Interní Med. 2014; 16(4): 164-166

Renal insufficiency in patient with free light chain myeloma

MUDr.Irena Kurfürstová1, MUDr.Tomáš Šálek1, MUDr.Eva Kadlčková2
1 Oddělení klinické biochemie, Krajská nemocnice T. Bati a.s., Zlín
2 Hematologicko-transfuzní oddělení, Krajská nemocnice T. Bati a.s., Zlín

Multiple myeloma is a malignant lymphoproliferative disease of B lymphocytes leading to the production of monoclonal immunoglobulin.

It accounts for 1 % of all malignancies and 10 % of hematology malignancies. The clinical picture is nonspecific. Early diagnosis is the

most important prerequisite for good treatment outcomes and prognosis. We present the case study of lady who presented with renal

insufficiency as the first sign of the disease.

Keywords: multiple myeloma, free light chains, chronic kidney disease, renal insufficiency

Published: June 1, 2014  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Kurfürstová I, Šálek T, Kadlčková E. Renal insufficiency in patient with free light chain myeloma. Interní Med. 2014;16(4):164-166.
Download citation

References

  1. Maisnar V., Tichý M. Monoklonální imunoglobuliny - výskyt, význam a možnosti jejich průkazu. 1. vyd. Praha: Nucleus HK, 2012.
  2. Kyle Robert A., Morie A. Gertz, Thomas E. Witzig, John A. Lust, Martha Q. Lacy, Angela Dispenzieri, Rafael Fonseca, S. Vincent Rajkumar, Janice R. Offord A Dirk R. Larson. Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clinic Proceedings. 2003, roč. 78, s. 21-33. Go to original source... Go to PubMed...
  3. Levey, Andrew S, Lesley A Stevens, Christopher H Schmid, Yaping Lucy Zhang, Alejandro F Castro 3rd, Harold I Feldman, John W Kusek, Paul Eggers, Frederick Van Lente, Tom Greene, Josef Coresh a CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration). A new equation to estimate glomerular filtration rate. Annals of internal medicine. 2009, roč. 150, č. 9, s. 604-612. Go to original source...
  4. Adam, Z., L. Pour, M. Krejčí, S. Štěpánková, I Svobodová, K. Veselý A R. Hájek. Poškození ledvin při mnohočetném myelomu a dalších monoklonálních gamapatiích. Vnitřní lékařství. 2008, roč. 54, č. 9, s. 847-861. Go to PubMed...
  5. Tesař, V., T. Zima, J. Racek, V. Teplan, B. Fridecký, J. Kratochvíla, J. Granátová a Z. Kubíček. Doporučení České nefrologické společnosti a České společnosti klinické biochemie ČLS JEP k vyšetřování proteinurie. Klinická biochemie a metabolismus. 2011, roč. 19, č. 1, s. 28-35.
  6. Adam, Z., J. Bačovský a R. Hájek. Diagnostika a léčba mnohočetného myelomu. Doporučení vytvořené Českou myelomovou skupinou, Myelomovou sekcí České hematologické společnosti a experty Slovenské republiky pro diagnostiku a léčbu mnohočetného myelomu. Transfuze a hematologie dnes. 2005, roč. 11, č. 1, s. 2-50.
  7. Kumar, Shaji K., S. Vincent Rajkumar, Angela Dispenzieri, Martha Q. Lacy, Suzanne R. Hayman, Francis K. Buadi, Steven R. Zeldenrust, David Dingli, Stephen J. Russell, John A. Lust, Philip R. Greipp, Robert A. Kyle a Morie A. Gertz. Improved survival in multiple myeloma and the impact of novel therapies. Blood. 2008, roč. 111, č. 5, s. 2516-2520. Go to original source... Go to PubMed...
  8. Bergsagel, P. Leif. Where We Were, Where We Are, Where We Are Going: Progress in Multiple Myeloma. Journal of Clinical Oncology [online]. nedatováno [vid. 2. červen 2014]. ISSN 0732-183X. Dostupné z: http://meetinglibrary.asco.org/content/114000199-144.
  9. Chanan-Khan, Ashera., Sagar Lonial, Donna Weber, Ivan Borrello, Robin Fo?, Andrzej Hellmann, Meletios Dimopoulos, Arlenes. Swern a Robert Knight. Lenalidomide in combination with dexamethasone improves survival and time-to-progression in patients >=65 years old with relapsed or refractory multiple myeloma. International Journal of Hematology. 2012, roč. 96, č. 2, s. 254-262. Go to original source... Go to PubMed...




Internal Medicine for Practice

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.